Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease
Carregando...
Citações na Scopus
42
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Citação
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, v.23, n.8, p.876-883, 2016
Resumo
Objective: The aim of the study was to evaluate the effectiveness of aerobic physical activity in reducing the frequency of hepatic steatosis and metabolic and cardiovascular risk in postmenopausal women with nonalcoholic fatty liver disease (NAFLD). Methods: Forty sedentary postmenopausal women (mean age 55.3 +/- 8.0 y) with biopsy-proven NAFLD were randomly divided into two groups: an exercising group (19 participants) and a control group (nonexercising, 21 participants). The exercise group underwent a supervised aerobic physical activity program of 120 min/wk for 24 weeks. The anthropometric parameters; body composition; hepatic, lipid, and glycemic profiles; homeostasis model assessment of insulin resistance index; cytokines; transient elastography (FibroScan; liver stiffness/controlled attenuation parameter); and cardiopulmonary exercise test were evaluated at baseline and after 24 weeks of protocol. Results: At baseline there were no significant differences in anthropometric, metabolic, and inflammatory parameters-stiffness and liver fat content by FibroScan between the groups. After 24 weeks, we observed a decrease of waist circumference, an increase of high-density lipoprotein cholesterol levels (P < 0.05), and improved cardiopulmonary functional capacity in the exercise group. In addition, the controlled attenuation parameter analysis showed no significant decrease of hepatic steatosis in the exercise group. With regard to the systemic inflammation, there were, however, no significant differences in the cytokines between the groups. Conclusions: An aerobic physical activity program of 24 weeks in NAFLD postmenopausal women showed improvement in some variables such as waist circumference, high-density lipoprotein cholesterol, and cardiopulmonary performance that may be beneficial in improving cardiovascular risk factors in this population.
Palavras-chave
Aerobic physical activity, Nonalcoholic fatty liver disease, Postmenopausal women
Referências
- Adams LA, 2005, DIABETIC MED, V22, P1129, DOI 10.1111/j.1464-5491.2005.01748.x
- Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
- Aldhahi Waleed, 2003, Curr Diab Rep, V3, P293, DOI 10.1007/s11892-003-0020-2
- Angulo P, 2007, ALIMENT PHARM THERAP, V25, P883, DOI 10.1111/j.1365-2036.2007.03246.x
- Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775
- Duarte SMB, 2014, NUTR HOSP, V29, P94, DOI 10.3305/nh.2014.29.1.7068
- Castera L, 2008, J HEPATOL, V48, P835, DOI 10.1016/j.jhep.2008.02.008
- de Ledinghen V, 2012, LIVER INT, V32, P911, DOI 10.1111/j.1478-3231.2012.02820.x
- de Ledinghen V, 2010, EXPERT REV MED DEVIC, V7, P811, DOI [10.1586/erd.10.46, 10.1586/ERD.10.46]
- Domanski JP, 2012, J CLIN GASTROENTEROL, V46, P427, DOI 10.1097/MCG.0b013e31822fb3f7
- Dowman JK, 2010, QJM-INT J MED, V103, P71, DOI 10.1093/qjmed/hcp158
- Fan JG, 2009, J HEPATOL, V50, P204, DOI 10.1016/j.jhep.2008.10.010
- George AS, 2009, HEPATOLOGY, V50, P68, DOI 10.1002/hep.22940
- Gulati M, 2003, CIRCULATION, V108, P1554, DOI 10.1161/01.CIR.0000091080.57509.E9
- Gutierrez-Grobe Ylse, 2010, Ann Hepatol, V9, P402
- Irwin ML, 2003, JAMA-J AM MED ASSOC, V289, P323, DOI 10.1001/jama.289.3.323
- Johnson NA, 2009, HEPATOLOGY, V50, P1105, DOI 10.1002/hep.23129
- Kelley GA, 2009, PREV MED, V48, P9, DOI 10.1016/j.ypmed.2008.10.010
- Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
- Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706
- Lavie CJ, 2009, AM J MED SCI, V338, P486, DOI 10.1097/MAJ.0b013e3181c61b66
- Lee DC, 2011, CIRCULATION, V124, P2483, DOI 10.1161/CIRCULATIONAHA.111.038422
- Lim S, 2015, INT J CARDIOL, V201, P408, DOI 10.1016/j.ijcard.2015.08.107
- Lyerly GW, 2009, MAYO CLIN PROC, V84, P780, DOI 10.1016/S0025-6196(11)60487-4
- Machado M, 2006, CURR OPIN CLIN NUTR, V9, P637, DOI 10.1097/01.mco.0000241677.40170.17
- Mann S, 2014, SPORTS MED, V44, P211, DOI 10.1007/s40279-013-0110-5
- Manousou P, 2011, LIVER INT, V31, P730, DOI 10.1111/j.1478-3231.2011.02488.x
- Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
- MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
- Newton JL, 2008, GUT, V57, P807, DOI 10.1136/gut.2007.139303
- Pettersson J, 2008, BRIT J CLIN PHARMACO, V65, P253, DOI 10.1111/j.1365-2125.2007.03001.x
- Soares FHR, 2013, WOMEN HEALTH, V53, P298, DOI 10.1080/03630242.2013.782940
- Sanchez-Munoz V, 2013, REV INVEST CLIN, V65, P307
- Sasso M, 2010, ULTRASOUND MED BIOL, V36, P1825, DOI 10.1016/j.ultrasmedbio.2010.07.005
- Simonen P, 2011, J HEPATOL, V54, P153, DOI 10.1016/j.jhep.2010.05.037
- Stepanova M, 2012, CLIN GASTROENTEROL H, V10, P646, DOI 10.1016/j.cgh.2011.12.039
- Suzuki Ayako, 2009, Womens Health (Lond), V5, P191, DOI 10.2217/17455057.5.2.191
- Troseid M, 2009, METAB SYNDR RELAT D, V7, P579, DOI 10.1089/met.2009.0003
- van der Heijden GJ, 2010, OBESITY, V18, P384, DOI 10.1038/oby.2009.274
- WASSERMAN K, 1973, J APPL PHYSIOL, V35, P236
- Zelber-Sagi S, 2014, WORLD J GASTROENTERO, V20, P4382, DOI 10.3748/wjg.v20.i15.4382